Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

Condition(s) studied

Investigational drug(s) / intervention(s)

induction therapy: induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy

Study summary

In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.

Eligibility

Primary outcome measure(s)

• patients completing definitive therapy — 1 year
  proportion of patients completing definitive therapy

Trial sites (1)

Other trials for the same condition